Shiguan Le1, Jian Xiao1, Wei Li1,2, Jing Wang1, Qing Wang1, Wang Xi1, Jibin Xu1, Zhinong Wang1. 1. Department of Cardiothoracic Surgery, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China. 2. Department of Cardiothoracic Surgery, 161 Hospital of Chinese People's Liberation Army, Wuhan 430012, China.
Abstract
BACKGROUND: Any cardiac surgery under cardiopulmonary bypass (CPB) will induce ischemia-reperfusion injury and systematic inflammatory response, which may lead to exacerbation. Conventional therapy strategy is to use inotropes, diuretics and vasodilator drugs, yet, the therapeutic effects of which need to be improved. Recombinant human B-type natriuretic peptide (rhBNP) has been shown to be efficacious in the treatment of acute decompensated heart failure and acute myocardial infarction. However, the effects of rhBNP on patients carried out CPB surgery is unknown. METHODS: We retrospect 357 patients carried out CPB surgery between Jan 1st 2014 and Dec 31st 2015 of our department. And according the use of rhBNP, these patients were divided into two groups: rhBNP group and control group. Patients in rhBNP group were received continuous intravenous rhBNP (0.0075-0.01 µg/kg/min) in 6 hours after CPB surgery, for a period of 72 h. Hemodynamic parameters were measured immediately after CPB surgery, and then at 2, 4, 8, 12 and 24 h after surgery. Blood samples were obtained immediately after surgery and thereafter once a day at 6:00 AM within the first 3 days after surgery. The daily urine volume as well as the time of tracheal intubation, ICU stay and chest drainage were also recorded. RESULTS: The baseline characteristics and heart functions were well balanced between two groups, and no patient died in the surgery. It showed significant differences in time-dependent changes in both groups of MAP (P<0.0001, within groups), MPAP (P<0.0001, within groups), PAWP (P<0.0001, within groups), CI (P<0.0001, within groups), SVRI (P<0.0001, within groups), serum BNP (P<0.0001, within groups), CK-MB (P<0.0001, within groups), troponin (P<0.0001, within groups) and creatinine (P<0.0001, within groups). It also showed significant differences in time-dependent changes between the two groups of MAP (P=0.04, between groups), PAWP (P=0.04, between groups), serum troponin (P<0.0001, between groups), serum creatinine (P<0.0001, between groups) and urine volume (P<0.0001, between groups). Interestingly, our results showed that patients in rhBNP group tended to wean off the respirator half a day later than those in control group (P=0.05), while no significant difference showed in both the length of chest drainage time and intensive care unit stay between the two groups. CONCLUSIONS: The administration of rhBNP can improve heart and renal function in patients underwent CPB surgery as well as accelerating the recovery from myocardial injury. But the prognosis of the patients who were administrated rhBNP did not improve in our study.
RCT Entities:
BACKGROUND: Any cardiac surgery under cardiopulmonary bypass (CPB) will induce ischemia-reperfusion injury and systematic inflammatory response, which may lead to exacerbation. Conventional therapy strategy is to use inotropes, diuretics and vasodilator drugs, yet, the therapeutic effects of which need to be improved. Recombinant human B-type natriuretic peptide (rhBNP) has been shown to be efficacious in the treatment of acute decompensated heart failure and acute myocardial infarction. However, the effects of rhBNP on patients carried out CPB surgery is unknown. METHODS: We retrospect 357 patients carried out CPB surgery between Jan 1st 2014 and Dec 31st 2015 of our department. And according the use of rhBNP, these patients were divided into two groups: rhBNP group and control group. Patients in rhBNP group were received continuous intravenous rhBNP (0.0075-0.01 µg/kg/min) in 6 hours after CPB surgery, for a period of 72 h. Hemodynamic parameters were measured immediately after CPB surgery, and then at 2, 4, 8, 12 and 24 h after surgery. Blood samples were obtained immediately after surgery and thereafter once a day at 6:00 AM within the first 3 days after surgery. The daily urine volume as well as the time of tracheal intubation, ICU stay and chest drainage were also recorded. RESULTS: The baseline characteristics and heart functions were well balanced between two groups, and no patient died in the surgery. It showed significant differences in time-dependent changes in both groups of MAP (P<0.0001, within groups), MPAP (P<0.0001, within groups), PAWP (P<0.0001, within groups), CI (P<0.0001, within groups), SVRI (P<0.0001, within groups), serum BNP (P<0.0001, within groups), CK-MB (P<0.0001, within groups), troponin (P<0.0001, within groups) and creatinine (P<0.0001, within groups). It also showed significant differences in time-dependent changes between the two groups of MAP (P=0.04, between groups), PAWP (P=0.04, between groups), serum troponin (P<0.0001, between groups), serum creatinine (P<0.0001, between groups) and urine volume (P<0.0001, between groups). Interestingly, our results showed that patients in rhBNP group tended to wean off the respirator half a day later than those in control group (P=0.05), while no significant difference showed in both the length of chest drainage time and intensive care unit stay between the two groups. CONCLUSIONS: The administration of rhBNP can improve heart and renal function in patients underwent CPB surgery as well as accelerating the recovery from myocardial injury. But the prognosis of the patients who were administrated rhBNP did not improve in our study.
Entities:
Keywords:
Cardiopulmonary bypass (CPB); effect; hemodynamics; recombinant human B-type natriuretic peptide (rhBNP); renal function
Authors: Markku S Nieminen; Michael Böhm; Martin R Cowie; Helmut Drexler; Gerasimos S Filippatos; Guillaume Jondeau; Yonathan Hasin; José Lopez-Sendon; Alexandre Mebazaa; Marco Metra; Andrew Rhodes; Karl Swedberg; Silvia G Priori; Maria Angeles Alonso Garcia; Jean-Jacques Blanc; Andrzej Budaj; Martin R Cowie; Veronica Dean; Jaap Deckers; Enrique Fernandez Burgos; John Lekakis; Bertil Lindahl; Gianfranco Mazzotta; João Morais; Ali Oto; Otto A Smiseth; Maria Angeles Alonso Garcia; Kenneth Dickstein; Anibal Albuquerque; Pedro Conthe; Maria Crespo-Leiro; Roberto Ferrari; Ferenc Follath; Antonello Gavazzi; Uwe Janssens; Michel Komajda; João Morais; Rui Moreno; Mervyn Singer; Satish Singh; Michal Tendera; Kristian Thygesen Journal: Eur Heart J Date: 2005-01-28 Impact factor: 29.983
Authors: Theophilus E Owan; Horng H Chen; Robert P Frantz; Barry L Karon; Wayne L Miller; Richard J Rodeheffer; David O Hodge; John C Burnett; Margaret M Redfield Journal: J Card Fail Date: 2008-05 Impact factor: 5.712
Authors: Horng H Chen; Kevin J Anstrom; Michael M Givertz; Lynne W Stevenson; Marc J Semigran; Steven R Goldsmith; Bradley A Bart; David A Bull; Josef Stehlik; Martin M LeWinter; Marvin A Konstam; Gordon S Huggins; Jean L Rouleau; Eileen O'Meara; W H Wilson Tang; Randall C Starling; Javed Butler; Anita Deswal; G Michael Felker; Christopher M O'Connor; Raphael E Bonita; Kenneth B Margulies; Thomas P Cappola; Elizabeth O Ofili; Douglas L Mann; Víctor G Dávila-Román; Steven E McNulty; Barry A Borlaug; Eric J Velazquez; Kerry L Lee; Monica R Shah; Adrian F Hernandez; Eugene Braunwald; Margaret M Redfield Journal: JAMA Date: 2013-12-18 Impact factor: 56.272
Authors: Emanuele Bobbio; Entela Bollano; Christian L Polte; Jan Ekelund; Göran Rådegran; Jakob Lundgren; Carl Haggård; Grunde Gjesdal; Oscar Braun; Sven-Erik Bartfay; Niklas Bergh; Pia Dahlberg; Clara Hjalmarsson; Sorosh Esmaily; Ida Haugen Löfman; Aristomenis Manouras; Michael Melin; Göran Dellgren; Kristjan Karason Journal: ESC Heart Fail Date: 2022-05-25
Authors: Jian Ling Liu; Xiao Fei Zhang; Zhi Liu; Jie Min Li; Zhen Jie Wen; Ming Zhang; Qin Han Lin; Qiu Ye Kou Journal: Medicine (Baltimore) Date: 2021-04-30 Impact factor: 1.817